Skip to content

Abstract B108: CXCR4 inhibition reprograms immune checkpoint networks and enhances anti-tumor immunity in patient-derived pancreatic cancer organoid–PBMC co-cultures

Sep 2026 · Cancer Research · 0 citations

TL;DR

A patient-specific ex vivo organoid model is developed to define CXCL12/CXCR4-mediated immune regulation and identify additional cellular and molecular targets to enhance antitumor efficacy and demonstrate that CXCR4 inhibition enhances immune-cell infiltration and activation, modulates checkpoint expression, and promotes tumor-cell killing, supporting combined CXCR4 and PD-1 blockade.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains largely refractory to immunotherapy because of its immunosuppressive, T-cell–excluded microenvironment. Immune checkpoint blockade, alone or with chemotherapy, has shown limited efficacy, likely due to redundant suppressive pathways. CAF-derived CXCL12 acting through CXCR4 is a key mediator of immune exclusion. We recently demonstrated a 65% response rate in a small phase II trial combining gemcitabine-based chemotherapy, CXCR4 inhibition, and PD-1 blockade. To build on this activity, we developed a patient-specific ex vivo organoid model to define CXCL12/CXCR4-mediated immune regulation and identify additional cellular and molecular targets to enhance antitumor efficacy. Patient-derived tumor organoids (PDTOs) were established from surgical resections of treatment-naïve patients with pancreatic cancer and co-cultured with matched peripheral blood mononuclear cells (PBMCs). PBMC migration toward PDTOs was assessed in a three-dimensional co-culture system. Immune-cell activation and infiltration and tumor-cell apoptosis were evaluated by flow cytometry and immunofluorescence. The effects of the CXCR4 antagonist AMD3100 on immune checkpoint receptor expression in PBMCs and corresponding ligand expression in PDTOs were assessed alone and with immune checkpoint blockade. Co-culture of PDAC patient–derived PBMCs with MiaPaCa-2 and PANC-1 cells and with allogeneic and autologous PDTOs reduced tumor cell numbers in the range of 3.5 to 4.9-fold. In contrast, PBMCs from healthy donors produced minimal tumor-cell killing. Relative to PBMC monoculture, patient-derived co-cultures increased activated CD69+ immune cells, including CD8+ T cells and CD56+ NK cells, with variable CD4+ T-cell activation; no lymphocyte activation was observed with healthy-donor PBMCs. AMD3100 pretreatment enhanced CD8+ T-cell migration toward autologous PDTOs in Matrigel and, following infiltration, increased PBMC proliferation and the abundance of activated T and NK cells expressing IFNγ, CD69, and granzyme B. CXCR4 inhibition also modulated PD-1, TIGIT, NKG2A, LAG-3, and TIM-3 expression in a patient-specific manner. PDAC-derived organoids expressed multiple immune-regulatory molecules, including PD-L1, TIGIT-L, HLA-E, CD73, FasL, IL-10, CXCL12, and calreticulin, indicating both checkpoint-dependent and soluble immune regulation. AMD3100 similarly altered checkpoint expression in PDTOs. Combined treatment of PBMCs and PDTOs with AMD3100 and PD-1 blockade further enhanced T-cell migration and activation and increased PDTO apoptosis, supporting the activity of this combination. Patient-specific PDTO–PBMC models demonstrate that CXCR4 inhibition enhances immune-cell infiltration and activation, modulates checkpoint expression, and promotes tumor-cell killing, supporting combined CXCR4 and PD-1 blockade. A randomized phase II trial evaluating this strategy with gemcitabine and nab-paclitaxel is ongoing. ILENIA PELLICCIOTTA, Gulam Manji, Alex Raufi, Emily Alouani. CXCR4 inhibition reprograms immune checkpoint networks and enhances anti-tumor immunity in patient-derived pancreatic cancer organoid–PBMC co-cultures [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B108.

View source

Similar papers

Oct 2026

Epigenetic Priming Sensitizes Metastatic Breast Cancer to Checkpoint Blockade by Rewiring the Tumor-Immune Microenvironment.

Work using metastatic mouse models shows that the antitumor response is multifactorial, comprising downregulation of myeloid-mediated CD8+ T-cell suppression along with increased B-cell and plasma cell activation, antibody production, and tertiary lymphoid structure (TLS) maturation.

Y. Senent, R. Manguso · 0 citations
Sep 2026

Abstract B054: Combined RAS Inhibition and Immune Checkpoint Blockade Overcome NF-κB-Mediated Immune Evasion in Chemoresistant Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Surgery is the only potentially curative treatment, yet approximately 85% of patients present with unresectable disease. For these patients, chemotherapy remains the standard treatment, though nearly all develop resistance and diseas...

K. Gulay, A. Martsinkovskiy, A. Lowy et al. · 0 citations
Sep 2026

Abstract B047: CXCR4 synergizes with multi-RAS inhibition by overcoming T cell exclusion to enhance immunogenic cancer cell death in human pancreatic cancer slice culture

The multi-RAS inhibitor, daraxonrasib, has demonstrated a remarkable improvement in outcomes for patients with metastatic PDAC. Pre-clinical murine studies have shown that the durable effects of the pre-clinical multi-RAS inhibitor, RMC-7977, require an intact immune system including CD8+ T cells and cross-presen...

Sheela R. Damle, Nancy Liu, Xiu-Yun Jiang et al. · 0 citations
Sep 2026

Abstract B083: Mutant KRAS cooperates with the hypoxic tumor microenvironment to drive immunosuppressive macrophages via a paracrine PGE2/GM-CSF axis

Hypoxia is known to drive an immunosuppressive microenvironment in pancreatic ductal adenocarcinoma (PDAC). However, the underlying immunosuppressive mechanisms remain unclear. Here, we hypothesized that hypoxia-induced factors secreted from tumor cells promoted immunosuppressive macrophages in PDAC. We tr...

Matthew T. Cribb, Ayeisha N. Colón-Ortiz, Sahar Fattani et al. · 0 citations
Open access Oct 2026

MHC-I downregulation is associated with immune-evasion in breast cancers with heterogeneous activation of epithelial-mesenchymal plasticity

Cancer cell-intrinsic epithelial-mesenchymal plasticity (EMP) drives carcinoma progression through increased intratumoral heterogeneity and an immunosuppressive tumor microenvironment (TME). Specifically, EMP activation in murine mammary carcinomas results in exclusion of CD8+ T-cells and recruitment of immunosuppressi...

Kimaya M. Bakhle, Andreas Stephanou, Sarthak Sahoo et al. · 0 citations
#gene editing Review Sep 2026

Abstract A129: Phasic Hedgehog Inhibition Primes the Pancreatic Tumor Microenvironment to Enhance Chemoimmunotherapy in Metastatic Pancreatic Ductal Adenocarcinoma: Results from the Phase 1b/2 NUMANTIA Trial

CAF-directed stromal priming as a strategy to enhance chemoimmunotherapy and warrant evaluation in randomized studies with integrated biomarker analyses are supported.

V. S. Kalluri, B. Bockorny, Evelio Perea Borobio et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.